Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Invivyd, Inc. (NASDAQ:IVVD) have been given an average rating of “Hold” by the six analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.00.

Several equities research analysts have recently commented on IVVD shares. BTIG Research reissued a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a report on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a report on Monday, December 29th.

Insider Buying and Selling

In other news, insider Timothy Edward Lee sold 20,964 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the transaction, the insider directly owned 117,717 shares in the company, valued at $185,992.86. The trade was a 15.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO William E. Duke sold 20,964 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the sale, the chief financial officer directly owned 107,717 shares in the company, valued at approximately $170,192.86. The trade was a 16.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 227,172 shares of company stock worth $354,534. Corporate insiders own 25.40% of the company’s stock.

Institutional Trading of Invivyd

Several institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its position in shares of Invivyd by 28.2% in the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock valued at $80,870,000 after buying an additional 7,160,065 shares during the last quarter. Perceptive Advisors LLC bought a new position in shares of Invivyd during the 4th quarter worth approximately $53,809,000. BVF Inc. IL acquired a new position in shares of Invivyd during the 4th quarter worth approximately $48,227,000. RA Capital Management L.P. acquired a new position in shares of Invivyd during the 3rd quarter worth approximately $18,831,000. Finally, ADAR1 Capital Management LLC bought a new stake in Invivyd in the 3rd quarter valued at $8,108,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Stock Down 13.1%

NASDAQ:IVVD opened at $1.19 on Tuesday. The firm has a market capitalization of $336.29 million, a price-to-earnings ratio of -3.72 and a beta of 0.61. Invivyd has a twelve month low of $0.46 and a twelve month high of $3.07. The stock’s 50 day moving average price is $1.70 and its two-hundred day moving average price is $1.91.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.